IMAB
Price
$3.48
Change
-$0.04 (-1.14%)
Updated
Sep 26 closing price
Capitalization
401.13M
46 days until earnings call
LYRA
Price
$6.47
Change
+$0.11 (+1.73%)
Updated
Sep 26 closing price
Capitalization
10.64M
Interact to see
Advertisement

IMAB vs LYRA

Header iconIMAB vs LYRA Comparison
Open Charts IMAB vs LYRABanner chart's image
I-MAB
Price$3.48
Change-$0.04 (-1.14%)
Volume$288.29K
Capitalization401.13M
Lyra Therapeutics
Price$6.47
Change+$0.11 (+1.73%)
Volume$7.27K
Capitalization10.64M
IMAB vs LYRA Comparison Chart in %
Loading...
IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LYRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMAB vs. LYRA commentary
Sep 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMAB is a Buy and LYRA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 28, 2025
Stock price -- (IMAB: $3.48 vs. LYRA: $6.47)
Brand notoriety: IMAB and LYRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMAB: 11% vs. LYRA: 37%
Market capitalization -- IMAB: $401.13M vs. LYRA: $10.64M
IMAB [@Biotechnology] is valued at $401.13M. LYRA’s [@Biotechnology] market capitalization is $10.64M. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMAB’s FA Score shows that 0 FA rating(s) are green whileLYRA’s FA Score has 0 green FA rating(s).

  • IMAB’s FA Score: 0 green, 5 red.
  • LYRA’s FA Score: 0 green, 5 red.
According to our system of comparison, IMAB is a better buy in the long-term than LYRA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMAB’s TA Score shows that 2 TA indicator(s) are bullish while LYRA’s TA Score has 5 bullish TA indicator(s).

  • IMAB’s TA Score: 2 bullish, 6 bearish.
  • LYRA’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, LYRA is a better buy in the short-term than IMAB.

Price Growth

IMAB (@Biotechnology) experienced а -8.18% price change this week, while LYRA (@Biotechnology) price change was +1.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.00%. For the same industry, the average monthly price growth was +9.18%, and the average quarterly price growth was +54.60%.

Reported Earning Dates

IMAB is expected to report earnings on Nov 13, 2025.

Industries' Descriptions

@Biotechnology (+4.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IMAB($401M) has a higher market cap than LYRA($10.6M). IMAB YTD gains are higher at: 309.412 vs. LYRA (-37.306). LYRA (-35.34M) and IMAB (-36.89M) have comparable annual earnings (EBITDA) . IMAB has more cash in the bank: 166M vs. LYRA (29.8M). IMAB has less debt than LYRA: IMAB (3.48M) vs LYRA (32.5M). LYRA has higher revenues than IMAB: LYRA (770K) vs IMAB (0).
IMABLYRAIMAB / LYRA
Capitalization401M10.6M3,783%
EBITDA-36.89M-35.34M104%
Gain YTD309.412-37.306-829%
P/E RatioN/AN/A-
Revenue0770K-
Total Cash166M29.8M557%
Total Debt3.48M32.5M11%
TECHNICAL ANALYSIS
Technical Analysis
IMABLYRA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
82%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
81%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
88%
Advances
ODDS (%)
Bullish Trend 7 days ago
77%
Bullish Trend 6 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 4 days ago
87%
BollingerBands
ODDS (%)
N/A
Bullish Trend 3 days ago
87%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LYRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NSANF2.550.09
+3.46%
Nissan Motor Co., Ltd.
MMTMF0.460.01
+1.48%
Monument Mining Ltd.
IPSOF43.50N/A
N/A
IPSOS
SABOF0.31N/A
N/A
Sabio Holdings Inc.
RHHBY39.59-0.37
-0.93%
Roche Holding Ltd

IMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMAB has been loosely correlated with INDP. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if IMAB jumps, then INDP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMAB
1D Price
Change %
IMAB100%
-1.14%
INDP - IMAB
38%
Loosely correlated
+6.40%
LYRA - IMAB
34%
Loosely correlated
+1.73%
RPRX - IMAB
31%
Poorly correlated
+0.40%
TPST - IMAB
28%
Poorly correlated
+0.75%
APLS - IMAB
27%
Poorly correlated
+0.68%
More

LYRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, LYRA has been closely correlated with ROQAF. These tickers have moved in lockstep 85% of the time. This A.I.-generated data suggests there is a high statistical probability that if LYRA jumps, then ROQAF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LYRA
1D Price
Change %
LYRA100%
+1.73%
ROQAF - LYRA
85%
Closely correlated
N/A
EYPT - LYRA
58%
Loosely correlated
+5.38%
VERA - LYRA
53%
Loosely correlated
+4.60%
KYMR - LYRA
51%
Loosely correlated
+4.68%
CLNN - LYRA
39%
Loosely correlated
+0.09%
More